A randomized, open‐label study to evaluate the safety and pharmacokinetics of human hepatitis C immune globulin (Civacir) in liver transplant recipients
Gary L. Davis, David R. Nelson, Norah Terrault, Timothy L. Pruett, Thomas D. Schiano, Courtney V. Fletcher, Christine V. Sapan, Laura N. Riser, Yufeng Li, Richard J. Whitley, John W. Gnann, Collaborative Antiviral Study Group – 20 July 2005 – Chronic hepatitis C is the most common indication for liver transplantation, but viral recurrence is universal and progressive graft injury occurs in most recipients.